Qualitas Health
Houston-based; AlmegaPL® — a triple-patented, EPA-only omega-3 from photoautotrophic Nannochloropsis — clinically shown to cut triglycerides 14% and remnant cholesterol up to 25%; FDA-listed as an NDI and TGA-listed in Australia, distributed globally via the SourceOne partnership (2024).
- Country
- United States
EPA-only Nannochloropsis
FDA NDI / TGA listed
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| aquaculture-seafood | ✓ | ✓ | — | ✓ |
| food-alt-protein | ✓ | ✓ | — | ✓ |
| marine-biotech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaefsanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Marine biotechnology | marine-biotech | Low | → |
| Microalgal omega-3 (EPA/DHA algal oils) | aquaculture-seafood | Low | → |
| Precision fermentation of fats & oils | food-alt-protein | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.